T 2220/14 (VelocImmune mouse/REGENERON) vom 09.11.2015
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2015:T222014.20151109
- Datum der Entscheidung
- 9. November 2015
- Aktenzeichen
- T 2220/14
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 02709544.7
- IPC-Klasse
- C12N 15/00
- Verfahrenssprache
- Englisch
- Verteilung
- An die Kammervorsitzenden verteilt (C)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- METHODS OF MODIFYING EUKARYOTIC CELLS
- Name des Antragstellers
- REGENERON PHARMACEUTICALS, INC.
- Name des Einsprechenden
- Kymab Limited
Merus B.V.
Novo Nordisk A/S - Kammer
- 3.3.08
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)
- Schlagwörter
- Postponement of the oral proceedings - (no)
Admission of documents (139), (161), (169) to (172) and (175) - (no)
Admission of documents (156), (158) and (168) - (yes)
Reopening debate - (no)
Confidentiality of documents (169) to (172) - (yes)
Admission of main request filed at the oral proceedings - (yes)
Requirements of the EPC fulfilled - (yes) - Orientierungssatz
- Sufficiency of disclosure - see sections 55 to 72
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the department of first instance with the order to maintain the patent on the basis of claims 1-6 of the main request received during the oral proceedings on 9 November 2015 at 16:00 hours, and a description to be adapted.